Stanga Lisa Loeb, Mujeeb Anwer, Packel Laura, Martz Tyler, Lemp George
1 California HIV/AIDS Research Program, University of California , Office of the President, Oakland, California.
2 Tobacco-Related Disease Research Program, University of California , Office of the President, Oakland, California.
AIDS Res Hum Retroviruses. 2017 Nov;33(S1):S1-S5. doi: 10.1089/AID.2017.0149.
This Special Issue of AIDS Research and Human Retroviruses features results from the HIV Cure Initiative, funded by the California HIV/AIDS Research Program (CHRP). As a publicly funded grant maker, CHRP has served for more than three decades as a unique resource for innovative researchers in California, whose work seeks to address all aspects of the HIV epidemic and the communities affected by it. Early initiatives at CHRP pioneered what would become enduring cornerstones of HIV science: isolation of the virus; efficacy and toxicities of the first HIV treatments; the emergence of drug resistance; the first biospecimen banks for HIV-related research; the first community-based laboratory service for HIV diagnostic serology; and the first longitudinal case-control study of progression from HIV to AIDS-The San Francisco General Hospital Cohort. More recently, CHRP-funded conceptual studies of zinc-finger nuclease-mediated disruption of CCR5 genomic sequences and the safety of solid organ transplantation for HIV-positive patients have progressed from brilliant ideas to clinical realities, and CHRP is currently funding the first multisite trial of HIV preexposure prophylaxis for transgender persons in the United States. The present article outlines the founding of CHRP, our current grantmaking process, and our impact on HIV research over time. In 2013, CHRP launched a new initiative aimed at moving the then nascent frontier of HIV cure science forward: the CHRP HIV Cure Initiative provided over $1.4 million to multiple basic biomedical research projects, and selected results are presented in this Special Issue.
本期《艾滋病研究与人类逆转录病毒》特刊展示了由加利福尼亚州艾滋病研究项目（CHRP）资助的“HIV治愈计划”的成果。作为一个由公共资金支持的资助机构，CHRP三十多年来一直是加利福尼亚州创新研究人员的独特资源，这些研究人员致力于解决艾滋病疫情的各个方面以及受其影响的社区问题。CHRP早期的举措开创了后来成为艾滋病科学持久基石的工作：病毒的分离；首批艾滋病治疗方法的疗效和毒性；耐药性的出现；首个用于艾滋病相关研究的生物样本库；首个基于社区的艾滋病诊断血清学实验室服务；以及首个从艾滋病病毒感染发展到艾滋病的纵向病例对照研究——旧金山综合医院队列研究。最近，由CHRP资助的关于锌指核酸酶介导的CCR5基因组序列破坏以及艾滋病病毒阳性患者实体器官移植安全性的概念性研究已从卓越的想法发展成为临床现实，并且CHRP目前正在资助美国首个针对跨性别者的艾滋病病毒暴露前预防多中心试验。本文概述了CHRP的成立、我们当前的资助流程以及我们长期以来对艾滋病研究的影响。2013年，CHRP发起了一项新倡议，旨在推动当时尚处于起步阶段的艾滋病治愈科学前沿发展：CHRP艾滋病治愈计划向多个基础生物医学研究项目提供了超过140万美元的资金，本期特刊展示了部分选定的研究成果。
